Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing virus-like drug conjugates (VDCs), a novel class of therapies for the treatment of multiple oncology indications. The Company’s lead VDC candidate, AU-011 (belzupacap sarotalocan), consists of a virus-like particle conjugated with an anti-cancer agent. AU-011 consists of human papillomavirus (HPV)-derived VLP conjugated to hundreds of infrared laser-activated molecules. AU-011 selectively targets and destroys cancer cells and activates the immune system with the potential to create long-lasting anti-tumor immunity. AU-011 is in development for ocular cancers and has initiated activities for the global Phase III trial evaluating first-line treatment of early-stage choroidal melanoma. It seeks to develop AU-011 across its ocular oncology franchise. In addition, the Company is developing AU-011 across multiple cancers, including in patients with non-muscle invasive bladder cancer.